Spelman, Tim, Ozakbas, Serkan, Soysal, Aysun, Kuhle, Jens, Sanchez-Menoyo, Jose Luis, Morgado, Yolanda Blanco, Spitaleri, Daniele L. A., Pesch, Vincent Van, Horakova, Dana, Ampapa, Radek, Patti, Francesco, Macdonell, Richard, Alroughani, Raed, Al-Asmi, Abdullah, Gerlach, O, Oh, J, Altintas, A, Tundia, N, Wong, SL, Butzkueven, H, MSBase Study Group,, Terzi, Murat, Hodgkinson, Suzanne, Laureys, Guy, Kalincik, Tomas, Der Walt, Anneke Van, Yamout, Bassem, Lechner-Scott, Jeannette. Future Medicine; 2023. A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.

Spelman, Tim, Ozakbas, Serkan, Soysal, Aysun, Kuhle, Jens, Sanchez-Menoyo, Jose Luis, Blanco Morgado, Yolanda, Spitaleri, Daniele L. A., van Pesch, Vincent, Horakova, Dana, Ampapa, Radek, Patti, Francesco, Macdonell, Richard, Alroughani, Raed, Al-Asmi, A, Gerlach, O, Oh, J, Altintas, A, Tundia, N, Wong, SL, Butzkueven, H, Terzi, Murat, Hodgkinson, Suzanne, Laureys, Guy, Kalincik, Tomas, Van Der Walt, Anneke, Yamout, Bassem, Lechner-Scott, Jeannette. Sage Publications; 2023. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.

Zhong, Michael, van der Walt, Anneke, Macdonell, Richard, Prevost, Julie, Kuhle, Jens, Laureys, Guy, Van Hijfte, Liesbeth, Alroughani, Raed, Kermode, Allan G., Butler, Ernest, Barnett, Michael, Eichau, Sara, Stankovich, Jim, van Pesch, V, Grammond, P, McCombe, P, Karabudak, R, Duquette, P, Girard, M, Taylor, B, Yeh, W, Monif, M, Gresle, M, Kalincik, Tomas, Butzkueven, H, Jokubaitis, VG, Buzzard, Katherine, Skibina, Olga, Boz, Cavit, Hodgkinson, Suzanne, Slee, Mark, Lechner-Scott, Jeanette. Sage Publications; 2022. Prediction of multiple sclerosis outcomes when switching to ocrelizumab.

Kalincik, Tomas, Sharmin, Sifat, Grigg, Andrew, Torkildsen, Øivind, Bo, Lars, Lehmann, Anne Kristine, Havrdova, Eva Kubala, Krasulova, Eva, Trnený, Marek, Kozak, Tomas, van der Walt, Anneke, Butzkueven, Helmut, Roos, Izanne, McCombe, Pamela, Skibina, O, Lechner-Scott, Jeanette, Willekens, B, Cartechini, E, Ozakbas, S, Alroughani, R, Kuhle, J, Patti, F, Duquette, P, Freedman, Mark S., Lugaresi, A, Khoury, SJ, Slee, M, Turkoglu, R, Hodgkinson, S, John, N, Maimone, D, Sa, MJ, van Pesch, V, Gerlach, O, Atkins, Harold, Laureys, G, Van Hijfte, L, Karabudak, R, Spitaleri, D, Csepany, T, Gouider, R, Castillo-Triviño, T, Taylor, B, Sharrack, B, Snowden, JA, Burman, Joachim, MSBase Study Group Collaborators,, MSBase Study Group Authors,, Mrabet, S, Garber, J, Sanchez-Menoyo, JL, Aguera-Morales, E, Blanco, Y, Al-Asmi, A, Weinstock-Guttman, B, Fragoso, Y, Massey, Jennifer, de Gans, K, Kermode, A, MSBase Study Group,, Sutton, Ian, Withers, Barbara, Macdonell, Richard. Amercian Medical Association; 2023. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.

Zhu, Chao, Zhou, Zhen, Alroughani, Raed, Lechner-Scott, Jeannette, Barnett, Michael, Izquierdo, Guillermo, Prat, Alexandre, Horakova, Dana, Havrdova, Eva Kubala, Macdonell, Richard, Patti, Francesco, Khoury, Samia Joseph, Roos, Izanne, Slee, M, Karabudak, R, Onofrj, M, Van Pesch, V, Prevost, J, Monif, M, Jokubaitis, V, van der Walt, A, Butzkueven, H, Merlo, Daniel, Kalincik, Tomas, Ozakbas, Serkan, Skibina, Olga, Kuhle, Jens, Hodgkinson, Suzanne, Boz, Cavit. BMJ Group; 2022. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.